Shenzhen, China, 4 March 2024 — MGI Tech, a company committed to building core tools and technology to lead life sciences, today proudly announced a milestone collaboration with Eurofins Genomics Europe Genotyping A/S (“Eurofins Genomics”), which has placed a corporate order for the revolutionary DNBSEQ-T20×2 (“T20”) ultra-high-throughput sequencer, along with the genomics data centre ZTRON Appliance and a range of MGI’s state-of-the-art laboratory automation products and systems. This marks the first corporate order of the T20 in Europe, signalling a significant advancement in precision health initiatives across the continent.
“We are thrilled to work with Eurofins Genomics to leverage T20’s ultra-high throughput and remarkable cost-efficiency to empower large population genome projects worldwide. With this partnership, we hope to improve accessibility of cost-effective sequencing to researchers globally,” said Dr Yong Hou, General Manager of MGI Europe and Africa.
Powered by MGI’s proprietary DNBSEQ™ technology, the T20 represents a breakthrough in genetic sequencing, significantly reducing sequencing costs to below $100 per genome when running 50,000 whole genomes per year, garnering global attention. Specifically designed to address the most challenging sequencing scenarios, T20 caters to a wide array of high-throughput sequencing needs in scientific and clinical research, including WGS, WGBS, stLFR, single-cell sequencing, Stereo-seq, and more. Following its launch in February 2023, T20 has gained widespread adoption among leading research institutions and healthcare providers worldwide.
Founded in 1990, Eurofins Genomics is part of the Eurofins Scientific Group, a life science company with laboratories in over 50 countries and more than 55,000 employees. Eurofins Genomics is a key emerging player in specialty esoteric and molecular clinical diagnostic testing in Europe and the United States, offering a portfolio of over 200,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin, and purity of biological substances and products, as well as for innovative clinical diagnostics.
The collaboration between MGI and Eurofins Genomics signifies a synergy of expertise and resources that promises to drive advancement in genomics research and clinical applications. Both organisations are poised to further facilitate the development of personalised medicine and the improvement of healthcare outcomes worldwide.
For Research Use Only. Not for use in diagnostic procedures.
